RAPID DISPATCH
24/H dispatch
2 in stock
MD-TISSUE is a medical device designed to improve movement and reduce associated pain by counteracting physiological or pathological deterioration of the soft tissues that make up the extra-articular support system, such as tendons, ligaments and joint capsule.
USE MEDICAL STRICT. Medical device. Use reserved for dermatologists and aesthetic doctors because they require a medical procedure.
MD-TISSUE is an injectable class III medical device:
- Barrier effect against harmful agents, lubricating action and mechanical support in the context of ongoing drug therapies.
- It improves movement and contains physiological deterioration of joints and soft tissues (such as tendons and ligaments) due to ageing, poor posture, chronic diseases, trauma or pollutants.
- It can be combined with other treatments.
- GUNA S.P.A.
- NAME: MD-TISSUE
- COMPOSITION: Collagen of porcine origin, ascorbic acid, magnesium gluconate, pyridoxine hydrochloride, riboflavin, thiamine hydrochloride, NaCl, water for injectable preparations.
- PRESENTATION: 10 x 2ml.
- INDICATIONS: Reduces pain and improves joint and tissue mobility (tendons and ligaments).
- INJECTION DEPTH: Peri-articular administration: Insert the needle perpendicular to the skin plane at the required depth. Perform multiple microinjections of 0.3 - 0.5 ml each. Intradermal administration: Insert the needle to a depth of 4-6 mm. Perform microinjections of 0.2 - 0.3 ml into the tissue to be treated.
- PROTOCOL: 1-2 infiltrations per week to contain physiological soft tissue deterioration (tendons, ligaments, joint capsule). Results are evident from the third week but, depending on the patient's clinical situation, treatment can be continued up to the tenth week without risk.
- USE: Strict medical use.
- Vials: 10 x 2ml.
Tissues (tendons and ligaments).
Collagen of porcine origin, ascorbic acid, magnesium gluconate, pyridoxine hydrochloride, riboflavin, thiamin hydrochloride, NaCl, water for injectable preparations.
- The product should only be injected by trained operators, in a suitable environment, using aseptic technique.
- Injection test in patients with suspected hypersensitivity: if there is a history of allergic reactions, a preliminary intradermal/injective test and observation of the patient for at least 1 hour is recommended.
- Avoid immediate exercise/prolonged mobilisation of the treated area unless indicated.
- Do not extend treatment beyond 10 weeks unless clinically assessed; follow protocols indicated by the manufacturer.
- Do not use after the expiry date; use immediately after opening; do not use if the bottle is damaged.
MD-TISSUE is contraindicated in the following cases:
- Known hypersensitivity to components (e.g. collagen of porcine origin or other excipients).
- Septic processes or active local/articular infections: do not inject into infected areas or in the presence of an ongoing joint infection.
Scientific evidence proves the efficacy and safety of MD-TISSUE:
- In the treatment of tendinopathies (epicondylitis, Achilles tendinitis and supraspinatus tendinitis).
- In the treatment of connective tissue disorders (plantar fasciitis).
- In the treatment of scars and wounds.
MD-TISSUE is a collagen-based injectable medical device designed to reduce pain and improve the mobility of soft tissues, such as tendons, ligaments and joint capsules, by counteracting their physiological or pathological deterioration.
MD-TISSUE can be administered via periarticular microinjections (0.3 - 0.5 ml each) or intradermal injections (0.2 - 0.3 ml), depending on the area to be treated and the doctor's clinical assessment.
Results are generally observable from the third week of treatment; the protocol usually involves 1-2 infiltrations per week and can be continued for up to 10 weeks as clinically necessary.
Only qualified medical personnel, as this is an injectable medical device that requires sterile technique, accurate diagnosis and appropriate choice of injection depth.
It is contraindicated primarily in cases of hypersensitivity to the components of the product or in the presence of active local or joint infections in the area to be treated.